Pharmaceutical intermediates
Ponatinib Hydrochloride Intermediates
2 pharmaceutical intermediates for Ponatinib Hydrochloride. Indication: Acute lymphoblastic leukemia; Chronic myeloid leukemia.
About Ponatinib Hydrochloride
- Originator
- Ariad Pharmaceuticals Inc
- Indication
- Acute lymphoblastic leukemia; Chronic myeloid leukemia
- Approved Date
- 12/18/2020
- DS/DP
- 12/22/2026
Available intermediates
2 intermediates currently listed for Ponatinib Hydrochloride. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-(4-Methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline | 694499-26-8 | / | / |
| 3-Ethynylimidazolo[1,2 -b]pyridazine | 943320-61-4 | / | / |
Building toward Ponatinib Hydrochloride?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →